Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Get Free Report) EVP Shirley R. Kuhlmann sold 40,000 shares of Collegium Pharmaceutical stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $28.08, for a total transaction of $1,123,200.00. Following the sale, the executive vice president now directly owns 154,204 shares of the company's stock, valued at $4,330,048.32. This represents a 20.60 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.
Collegium Pharmaceutical Price Performance
Shares of COLL traded up $0.75 during mid-day trading on Monday, reaching $29.66. The stock had a trading volume of 388,231 shares, compared to its average volume of 422,500. The business has a fifty day moving average of $30.78 and a 200 day moving average of $33.19. Collegium Pharmaceutical, Inc. has a 12 month low of $27.28 and a 12 month high of $42.29. The firm has a market cap of $933.87 million, a price-to-earnings ratio of 12.78 and a beta of 0.99. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97.
Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share for the quarter, beating the consensus estimate of $1.54 by $0.09. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. The business had revenue of $181.95 million during the quarter, compared to analysts' expectations of $179.68 million. Equities analysts predict that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current year.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently bought and sold shares of COLL. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in Collegium Pharmaceutical in the 4th quarter worth approximately $3,489,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in Collegium Pharmaceutical by 11.9% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 66,389 shares of the specialty pharmaceutical company's stock worth $1,902,000 after purchasing an additional 7,063 shares in the last quarter. Velan Capital Investment Management LP acquired a new stake in Collegium Pharmaceutical during the fourth quarter worth approximately $822,000. Vident Advisory LLC grew its position in Collegium Pharmaceutical by 27.8% during the 4th quarter. Vident Advisory LLC now owns 16,898 shares of the specialty pharmaceutical company's stock worth $484,000 after purchasing an additional 3,672 shares during the last quarter. Finally, Virtus Fund Advisers LLC grew its position in Collegium Pharmaceutical by 30.5% in the 4th quarter. Virtus Fund Advisers LLC now owns 2,419 shares of the specialty pharmaceutical company's stock valued at $69,000 after buying an additional 565 shares during the last quarter.
Wall Street Analyst Weigh In
A number of equities analysts recently issued reports on the company. Needham & Company LLC upgraded Collegium Pharmaceutical from a "hold" rating to a "buy" rating and set a $46.00 target price on the stock in a report on Friday, January 10th. HC Wainwright reaffirmed a "buy" rating and issued a $50.00 price objective on shares of Collegium Pharmaceutical in a report on Friday, January 10th. Finally, Piper Sandler lowered their price objective on Collegium Pharmaceutical from $37.00 to $36.00 and set a "neutral" rating on the stock in a research report on Tuesday, February 4th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, Collegium Pharmaceutical presently has a consensus rating of "Moderate Buy" and a consensus price target of $43.60.
Check Out Our Latest Stock Analysis on COLL
Collegium Pharmaceutical Company Profile
(
Get Free Report)
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.
Recommended Stories
Before you consider Collegium Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Collegium Pharmaceutical wasn't on the list.
While Collegium Pharmaceutical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
